High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer

    Research output: Contribution to journalArticle

    38 Citations (Scopus)

    Abstract

    Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 μg/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50% reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6%, 95% CI, 0-28) achieved a confirmed PSA response. Four patients (24%, 95% CI, 7-49) had PSA reductions ranging from 24 to 38%. Of the 15 patients with a PPI ≥ 1 point on entry, 3 (18%, 95% CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone.

    Original languageEnglish (US)
    Pages (from-to)535-541
    Number of pages7
    JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
    Volume27
    Issue number5
    DOIs
    StatePublished - Oct 2004

    Fingerprint

    Calcitriol
    Carboplatin
    Androgens
    Prostatic Neoplasms
    Pain
    Area Under Curve
    Analgesics
    Prostate
    Adenocarcinoma
    Radiation

    Keywords

    • Calcitriol
    • Carboplatin
    • Chemotherapy
    • Prostate cancer
    • Vitamin D

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    @article{e916a7d17de14d9284d9623681e64bd8,
    title = "High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer",
    abstract = "Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 μg/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50{\%} reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6{\%}, 95{\%} CI, 0-28) achieved a confirmed PSA response. Four patients (24{\%}, 95{\%} CI, 7-49) had PSA reductions ranging from 24 to 38{\%}. Of the 15 patients with a PPI ≥ 1 point on entry, 3 (18{\%}, 95{\%} CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone.",
    keywords = "Calcitriol, Carboplatin, Chemotherapy, Prostate cancer, Vitamin D",
    author = "Beer, {Tomasz (Tom)} and Mark Garzotto and Katovic, {Nina M.}",
    year = "2004",
    month = "10",
    doi = "10.1097/01.coc.0000136020.27904.9c",
    language = "English (US)",
    volume = "27",
    pages = "535--541",
    journal = "American Journal of Clinical Oncology",
    issn = "0277-3732",
    publisher = "Lippincott Williams and Wilkins",
    number = "5",

    }

    TY - JOUR

    T1 - High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer

    AU - Beer, Tomasz (Tom)

    AU - Garzotto, Mark

    AU - Katovic, Nina M.

    PY - 2004/10

    Y1 - 2004/10

    N2 - Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 μg/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50% reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6%, 95% CI, 0-28) achieved a confirmed PSA response. Four patients (24%, 95% CI, 7-49) had PSA reductions ranging from 24 to 38%. Of the 15 patients with a PPI ≥ 1 point on entry, 3 (18%, 95% CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone.

    AB - Calcitriol acts synergistically with carboplatin in preclinical models of adenocarcinoma of the prostate. The authors sought to test high-dose oral calcitriol in combination with carboplatin in patients with metastatic androgen-independent prostate cancer. Seventeen patients received oral calcitriol (0.5 μg/kg) on day 1 and intravenous carboplatin (AUC 7 or AUC 6 in patients with prior radiation) on day 2, repeated every 4 weeks. PSA response was the primary end point and was defined as a 50% reduction confirmed 4 weeks later. Palliative response (2-point reduction or normalization of pain on the present pain intensity [PPI] scale without increased analgesic consumption) was also examined. One of 17 patients (6%, 95% CI, 0-28) achieved a confirmed PSA response. Four patients (24%, 95% CI, 7-49) had PSA reductions ranging from 24 to 38%. Of the 15 patients with a PPI ≥ 1 point on entry, 3 (18%, 95% CI, 4-48) met criteria for palliative response. Treatment-related toxicity was mild and generally similar to that expected with single-agent carboplatin. Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone.

    KW - Calcitriol

    KW - Carboplatin

    KW - Chemotherapy

    KW - Prostate cancer

    KW - Vitamin D

    UR - http://www.scopus.com/inward/record.url?scp=5644298421&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=5644298421&partnerID=8YFLogxK

    U2 - 10.1097/01.coc.0000136020.27904.9c

    DO - 10.1097/01.coc.0000136020.27904.9c

    M3 - Article

    C2 - 15596926

    AN - SCOPUS:5644298421

    VL - 27

    SP - 535

    EP - 541

    JO - American Journal of Clinical Oncology

    JF - American Journal of Clinical Oncology

    SN - 0277-3732

    IS - 5

    ER -